PMV PHARMACEUTICALS, INC. (PMVP) Quick Ratio
- Quick ratio · latest quarter: Value (m); Formula and calculation Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30..
Quick ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Quick ratio · latest quarter | (m) | Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Cash, securities and trade receivables | (m) | Cash and Cash Equivalents, at Carrying Value · Marketable Securities, Current · Debt Securities, Available-for-sale, Current |
| Current obligations | 10.57M USD | Liabilities, Current |
| Cash and equivalents | 12.47M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | 66.96M USD | Marketable Securities, Current · Debt Securities, Available-for-sale, Current |
| Customer receivables | (m) | |
| Inventory · excluded from quick assets | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Cash, securities and trade receivables (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory · excluded from quick assets (USD) | Quick ratio |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | $10.57M | $12.47M | $66.96M | (m) | (m) | (m) |
| 2026-03-31 | (m) | $8.60M | $39.13M | $54.42M | (m) | (m) | (m) |
| 2025-12-31 | (m) | $11.41M | $37.98M | $74.96M | (m) | (m) | (m) |
| 2025-09-30 | (m) | $12.30M | $36.34M | $92.91M | (m) | (m) | (m) |
| 2025-06-30 | (m) | $11.61M | $44.13M | $98.15M | (m) | (m) | (m) |
| 2025-03-31 | (m) | $9.76M | $51.34M | $109.05M | (m) | (m) | (m) |
| 2024-12-31 | (m) | $14.37M | $40.88M | $128.58M | (m) | (m) | (m) |
| 2024-09-30 | (m) | $13.56M | $48.81M | $134.03M | (m) | (m) | (m) |
| 2024-06-30 | (m) | $11.38M | $48.53M | $164.39M | (m) | (m) | (m) |
| 2024-03-31 | (m) | $12.06M | $47.65M | $150.28M | (m) | (m) | (m) |
| 2023-12-31 | (m) | $14.03M | $37.71M | $165.35M | (m) | (m) | (m) |
| 2023-09-30 | (m) | $10.72M | $52.06M | $149.86M | (m) | (m) | (m) |
| 2023-06-30 | (m) | $11.45M | $68.21M | $118.88M | (m) | (m) | (m) |
| 2023-03-31 | (m) | $10.59M | $142.94M | $86.49M | (m) | (m) | (m) |
| 2022-12-31 | (m) | $10.83M | $108.30M | $132.76M | (m) | (m) | (m) |
| 2022-09-30 | (m) | $11.66M | $99.85M | $159.01M | (m) | (m) | (m) |
| 2022-06-30 | (m) | $11.38M | $87.09M | $190.34M | (m) | (m) | (m) |
| 2022-03-31 | (m) | $11.69M | $115.77M | $167.22M | (m) | (m) | (m) |
| 2021-12-31 | (m) | $12.22M | $172.47M | $124.70M | (m) | (m) | (m) |
| 2021-09-30 | (m) | $8.56M | $176.64M | $131.01M | (m) | (m) | (m) |
| 2021-06-30 | (m) | $7.50M | $189.42M | $128.93M | (m) | (m) | (m) |
| 2021-03-31 | (m) | $5.80M | $208.78M | $122.71M | (m) | (m) | (m) |
| 2020-12-31 | (m) | $6.41M | $361.42M | (m) | (m) | (m) | (m) |
| 2020-09-30 | (m) | $5.48M | $373.15M | (m) | (m) | (m) | (m) |
| 2019-12-31 | (m) | $4.52M | $73.28M | $28.21M | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| TENAX THERAPEUTICS, INC. (TENX) | United States | $0.071B | -7.17 |
| Lunai Bioworks Inc. (LNAI) | United States | $0.072B | -0.11 |
| PLIANT THERAPEUTICS, INC. (PLRX) | United States | $0.071B | -0.76 |
| Yarrow Bioscience, Inc. (YARW) | United States | $0.070B | |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Connect Biopharma Holdings Ltd (CNTB) | $0.069B | -2.17 | |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |